TY - JOUR
T1 - Effectiveness and safety of multidrug intracavernous therapy for vasculogenic impotence
AU - Montorsi, Francesco
AU - Guazzoni, Giorgio
AU - Bergamaschi, Franco
AU - Dodesini, Alessandro
AU - Rigatti, Patrizio
AU - Pizzini, Giuliano
AU - Miani, Alberto
PY - 1993
Y1 - 1993
N2 - A four-drug vasoactive mixture (papaverine hydrochloride, prostaglandin E1, phentolamine mesylate, atropine sulfate) was used for intracavernous injection therapy in 94 patients with vasculogenic impotence as diagnosed by color Doppler sonography and dynamic infusion cavernosometry-cavernosography. At a mean follow-up of twenty months, 66 patients (70%) are using the injections with the initial dose and are satisfied; 14 patients (15%) are using the injections with a smaller dose than initially given; and 14 patients (15%) dropped intracavernous treatment. Only 4 patients (4%) were unable to achieve a sustained rigid erection during the mixture titration phase. Selected cases of vasculogenic impotence can be safely and effectively treated by the association of drugs which rely on different mechanisms of action, producing a pharmacologic synergism which enhances the overall therapeutic effect.
AB - A four-drug vasoactive mixture (papaverine hydrochloride, prostaglandin E1, phentolamine mesylate, atropine sulfate) was used for intracavernous injection therapy in 94 patients with vasculogenic impotence as diagnosed by color Doppler sonography and dynamic infusion cavernosometry-cavernosography. At a mean follow-up of twenty months, 66 patients (70%) are using the injections with the initial dose and are satisfied; 14 patients (15%) are using the injections with a smaller dose than initially given; and 14 patients (15%) dropped intracavernous treatment. Only 4 patients (4%) were unable to achieve a sustained rigid erection during the mixture titration phase. Selected cases of vasculogenic impotence can be safely and effectively treated by the association of drugs which rely on different mechanisms of action, producing a pharmacologic synergism which enhances the overall therapeutic effect.
UR - http://www.scopus.com/inward/record.url?scp=0027449428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027449428&partnerID=8YFLogxK
U2 - 10.1016/0090-4295(93)90272-C
DO - 10.1016/0090-4295(93)90272-C
M3 - Article
C2 - 7694416
AN - SCOPUS:0027449428
VL - 42
SP - 554
EP - 558
JO - Urology
JF - Urology
SN - 0090-4295
IS - 5
ER -